



ASX ANNOUNCEMENT

MEDLAB CLINICAL PRESENTS NANOCELLE® AT JEFFERIES HEALTHCARE CONFERENCE LONDON THE LARGEST HEALTHCARE-DEDICATED CONFERENCE IN EUROPE

Sydney, November 09, 2022 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to announce Dr Sean Hall, CEO is speaking 5:30PM GMT Wednesday, 16 November 2022 (equivalent to 4:30am Thursday, 17 November 2022 AEST) at the Jefferies Healthcare Conference on the company's robust, patented delivery platform NanoCelle®, its use in NanaBis™ as well as 30+ other drug potentials.

NanoCelle® is the lead delivery platform for the company. This allows for the creation of safe and effective nanoparticles encapsulating a potential medicine. Once within the NanoCelle® environment, the medicine can be delivered in ways that reduce potential patient risk, improve absorbability, and increase patient compliance, allowing for a safer, more tolerable medicine and patient experience. Dr Hall will emphasise during the talk the need to "bypass first pass metabolism" and why this is very important, especially as it relates to cannabinoids and the adverse effects associated with "typical" use.

A webcast system has been made available for this presentation, to register please use the following URL: <https://wsw.com/webcast/jeff255/mdc.ax/2053485>

For those unable to attend due to the inconvenient time in Australia, on completion of the live webcast it will be available to be viewed for 90 days in the above link.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical Ltd (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co *Medlab – better medicines, better patient care*

Medlab Clinical Ltd

Dr. Sean Hall

T: +61 411 603 378

E: sean_hall@medlab.co

Medlab Clinical Limited

Building A, Units 5 & 6, 11-13 Lord St, Botany, NSW 2019

P: +61 2 8188 0311 F: +61 2 9699 3347 W: www.medlab.co